3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis
- Booij, Tijmen H. ORCID NEXUS Personalized Health Technologies, ETH Zürich, Switzerland
- Price, Leo S. OcellO B.V., Leiden, The Netherlands
- Danen, Erik H. J. ORCID Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
- 2019-2-28
Published in:
- SLAS DISCOVERY: Advancing the Science of Drug Discovery. - SAGE Publications. - 2019, vol. 24, no. 6, p. 615-627
English
The introduction of more relevant cell models in early preclinical drug discovery, combined with high-content imaging and automated analysis, is expected to increase the quality of compounds progressing to preclinical stages in the drug development pipeline. In this review we discuss the current switch to more relevant 3D cell culture models and associated challenges for high-throughput screening and high-content analysis. We propose that overcoming these challenges will enable front-loading the drug discovery pipeline with better biology, extracting the most from that biology, and, in general, improving translation between in vitro and in vivo models. This is expected to reduce the proportion of compounds that fail in vivo testing due to a lack of efficacy or to toxicity.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1177/2472555219830087
- ISSN 2472-5552
- Persistent URL
- https://sonar.ch/global/documents/76276
Statistics
Document views: 5
File downloads:
- fulltext.pdf: 0